Each year, an estimated 14,000 women aged ≤40 years are diagnosed with breast cancer, which remains the leading cause of cancer-related death in this patient population. Several studies have shown that breast cancer has more aggressive biological characteristics in women aged <40 years compared with older women, including higher likelihood of high-grade, estrogen receptor–negative tumors, and lymph node (LN)–positive disease. However, due to a higher proportion of HER2-positive and triple-negative breast cancer (TNBC) in this group, these women are also more likely to have pathologic complete response (pCR) following neoadjuvant chemotherapy (NAC), which has been extensively studied as a surrogate marker for improved prognosis. Clinical trials specifically focusing on this high-risk patient population have not been undertaken, and treatment recommendations are made from extrapolation of available data from trials that predominantly included older, frequently postmenopausal, women.

In addition to pCR, complete pathologic nodal response (ypN0) has emerged as a strong predictor of disease-free survival (DFS) and overall survival (OS) in the...
neoadjuvant setting, however its prognostic potential has not been investigated in women aged ≤40 years. The current debate centers on whether women who attain either pCR or ypN0 after NAC should receive adjuvant radiation treatment in the form of regional nodal irradiation or postmastectomy radiation, or whether this can be omitted. In a pooled analysis of NSABP B-18 and B-27, attaining pathologic nodal response emerged as a strong predictor of DFS and OS. Another analysis of these 2 studies by Mamounas et al showed that younger patients who achieve ypN0 have a higher 10-year probability of locoregional recurrence (LRR) compared with women aged >60 years; the exact risk for LRR in women aged <40 years was not presented. In addition, pathologic nodal status and breast tumor response were predictive of LRR and suggested that, due to low rates of LRR in favorable subgroups, adjuvant regional nodal irradiation and postmastectomy radiation could possibly be omitted. This forms the basis of the rationale for the ongoing NSABP B-51/RTOG 1304 trial (ClinicalTrials.gov identifier: NCT01872975).

Our study evaluated pathologic nodal response in women aged ≤40 years treated with NAC for breast cancer, and hypothesized that it would be associated with DFS and OS in this patient population.

Methods

We conducted an Institutional Review Board–approved, retrospective, single-institution analysis of women diagnosed with breast cancer at age ≤40 years and treated between 1991 and 2015. A total of 155 patients were identified, 40 and 115 of whom were diagnosed and treated between 1991–2004 and 2005–2015, respectively. All patients received NAC and surgery with or without radiation therapy (RT). Pathologic confirmation of axillary nodal involvement by fine-needle aspiration was not required for inclusion in our analysis. Patients were excluded if surgical or RT records were not available at the time of data analysis, if they had metastatic disease at diagnosis, or if they received chemotherapy for other cancer diagnoses. pCR was defined as no evidence of residual invasive tumor in the breast and sampled axillary LNs (ypT0/Tis ypN0). All other patients were considered to have partial response if there was no tumor in the LNs but residual tumor in the breast (ypT+ ypN0) or no tumor in the breast but residual tumor in the LNs (ypT0/Tis ypN+). Those who had residual tumor in both the breast and LNs were classified as having a limited response (ypT+ ypN+). Residual cancer burden was not routinely assessed in all pathology samples, and therefore was not included in this analysis.

All patients included in this study had detailed clinical and pathologic information available for review, such as clinical stage at diagnosis, hormone receptor (HR) status, HER2 status, Ki67 percentage, BRCA1/2 mutation status, type of NAC, use of HER2-targeted therapy and hormonal therapy, size of residual disease, LN involvement, presence of lymphovascular invasion, and achievement of pCR. Local (LF), regional (RF), and distant (DF) failure were recorded for each patient.

All statistical analysis was conducted using SAS version 9.4 (SAS Institute Inc.). Competing risks analysis was performed using the Fine-Gray method to analyze cumulative incidence of LF, RF, and DF for each site; hazard ratios were reported with a 95% CI, and OS was calculated using Kaplan-Meier and log-rank tests. Multivariable analysis was performed with Cox proportional hazards regression using select prognostic parameters identified as significant on competing risks analysis. Statistical significance was determined as a 2-sided P value <.05.

Results

A total of 155 patients were included in this analysis. Median age was 36 years (range, 20–40 years), and median follow-up time was 52 months (range, 6–293 months). The median OS for the entire cohort was 122 months. Table 1 details the clinical characteristics. In brief, 97 patients (62.5% of the entire cohort) had genetic test results available for BRCA, of which 25.8% (n=25) carried BRCA1 mutations and 7.2% (n=7) carried BRCA2 mutations. Initial clinical stage at diagnosis was stage I in 4%, stage II in 45%, and stage III in 46%. All patients received NAC followed by mastectomy (n=108; 69.7%) or lumpectomy (n=47; 30.3%). A total of 132 (85.2%) patients received adjuvant RT; 42 of 47 (89.4%) after lumpectomy (5 refused) and 90 of 108 (83.3%) after mastectomy.

After NAC, 39 patients (25.2%) achieved pCR (ypT0/Tis ypN0), 52 (33.5%) achieved ypT+ ypN0, and 5 (3.2%) achieved ypT0/Tis ypN+. The remain-
ing 59 patients (38.1%) were found to have residual disease in both the breast and the LNs (ypT+ ypN+) at the time of final pathologic review. Because only 5 patients achieved ypT0/Tis ypN0, the cohort was subsequently grouped into 3 subsets: patients who attained pCR (n=39) and those who did not attain pCR and were either LN-negative (ypT+ ypN0; n=52) or LN-positive (ypN+; n=64).

A total of 22 patients (14.2%) experienced LF, 20 (12.9%) experienced RF, and 59 (38.1%) experienced DF. LRR occurred among 22 of 108 patients (20.4%) who underwent mastectomy and 8 of 47 (17.0%) who underwent lumpectomy, and DF occurred in 46 of 108 of patients (43.6%) who underwent mastectomy and 13 of 47 (27.6%) who underwent lumpectomy. No local or regional recurrences occurred in patients who achieved pCR. A total of 3 patients (7.7%) with pCR developed distant metastases, 2 of whom were still alive with disease at time of writing, and 1 who died 96 months after the initial diagnosis. However, patients with residual disease in either the breast or LNs had a higher incidence of LF, RF, and DF than those who achieved pCR (Figure 1), with approximately 50% experiencing DF at 10 years (P<.001; Table 2). Of those who achieved a pCR in the LNs, patients who still had residual disease in the breast did not have better outcomes compared with those who remained LN-positive. Cumulative incidence of LF, RF, and DF at 10 years by response to NAC is depicted in Table 2, with corresponding cumulative incidence curves in Figure 1. Median OS for patients with pCR was not reached (P<.001). No significant difference in OS was seen between ypT+ ypN0 versus ypN+ patients, with median OS of 97 versus 83 months, respectively (P=.25) (Figure 2A).

To evaluate whether modern systemic therapy affected OS, we stratified patients into 2 groups based on treatment date and chose a cutoff of 2005, because this was when the use of trastuzumab for HER2-positive breast cancer had become standard of care. On Kaplan-Meier analysis, no difference in OS was seen between ypT+ ypN0 versus ypN+ patients, with median OS of 97 versus 83 months, respectively (P=.88). We next analyzed patients treated between 2005–2015 (n=116) separately to evaluate outcomes in a patient population with routine HER2 testing and regular use of trastuzumab. Patients with ypT+ ypN0 and ypN+ disease continued to have worse OS compared with those who achieved pCR, with median OS not reached for the pCR group, and 84 versus 77 months, respectively, for patients with ypT+ ypN0 and ypN+ disease (P<.001; Figure 2B). We also evaluated outcomes of patients with an initial diagnosis of clinical T1–3N1 breast cancer (n=115) who achieved pCR in the LNs (ypT0/Tis ypN0 and ypT+ ypN0) following NAC, because this group is included in the ongoing NSABP B-51 trial. We found that outcomes of patients who achieved pCR were excellent, with median OS not reached (P=.03; Figure 2C); how-
ever, patients with ypT+ ypN0 disease did not have improved OS compared with those who remained ypN+ after NAC, with a median OS of 84 versus 107 months, respectively. On multivariable analysis, mastectomy (P=.009), adjuvant RT (P=.045), achievement of pCR (P<.001), and total LNs sampled (P=.011) were all predictive of OS (Table 3).

Lastly, we investigated the impact of breast cancer subtype on outcomes. Patients were divided into 4 groups: HR-positive/HER2-negative (n=60; 39.2%), HR-positive/HER2-positive (n=21; 13.7%), HR-negative/HER2-positive (n=17; 11.1%), and TNBC (n=55; 35.9%); subtype was not available for 2 patients. pCR by breast cancer subtype was 18.3% for HR-positive/HER2-negative, 23.8% for HR-positive/HER2-positive, 35.3% for HR-negative/HER2-positive, and 31% for TNBC. Median OS was not reached for the HR-positive/HER2-positive and TNBC cohorts, was 170 months in the HR-positive/HER2-negative cohort, and was 96 months in the HR-negative/HER2-positive cohort (P=.03). OS by subtype and pCR is shown in supplemental eFigure 1 (available with this article at JNCCN.org).

Discussion

To our knowledge, this is the first study evaluating outcomes by pathologic nodal response in women aged ≤40 years treated with NAC. We focused on young women treated with NAC because this population is infrequently studied on its own, yet has worse survival compared with older women despite higher rates of pCR. In addition, although the secondary analysis of NSABP B-18 and B-27 has been used to guide risk assessment following NAC, it does not include a comprehensive analysis of recurrence risk in women aged ≤40 years. Our report presents LF, RF, and DF rates in this high-risk breast cancer population, making this analysis unique with respect to the published literature.

Our analysis reveals that women aged ≤40 years with residual disease in the breast or LNs have increased LRR rates compared with those who achieve pCR in both the breast and LNs. Perhaps the most compelling finding of our analysis is that women with residual disease in the breast, despite having a pCR in the LNs, had similar LRR rates as those with residual nodal disease. This important finding suggests that omitting RT in patients with any residual disease after NAC, whether in the breast alone or in the breast and LNs, should be considered with caution. The LRR rates remained between 15% and 22% in patients with ypT+ ypN0 and ypN+ disease, even though most patients in our study received...
Pathologic Nodal Response and Outcomes

As those who have residual disease in the breast, de
mumab in the neoadjuvant setting.
This led to the accelerated FDA approval of pertu
comes in women with HER2-positive breast cancer.
As these women would benefit from adjuvant treatment
to improve outcomes, and several trials have evalu
ated escalation of adjuvant therapy.\textsuperscript{16-18} The recently
published CREATE-X trial\textsuperscript{19} evaluated 910 patients
with HER2-negative breast cancer who had residual
invasive disease or LN metastases after NAC. Wom
were randomized to either adjuvant capecitabine or
observation. At 5 years of follow-up, the addition
of adjuvant capecitabine significantly prolonged DFS
and OS. Other efforts to improve outcomes center
around increasing rates of pCR through the escala
tion of NAC regimens.\textsuperscript{16-18} In the 5-year follow-up
of the NeoSphere trial,\textsuperscript{22} the addition of pertuzumab
to trastuzumab + docetaxel improved long-term out
comes in women with HER2-positive breast cancer.
This led to the accelerated FDA approval of pertu
zumab in the neoadjuvant setting.\textsuperscript{23}

Our analysis shows that young women with breast
cancer who achieve a pCR in both the breast and the LNs experience improved outcomes, whereas those who have residual disease in the breast, de-

---

Table 3. Multivariable Analysis of Prognostic Variables for Overall Survival

<table>
<thead>
<tr>
<th>Variable</th>
<th>P Value</th>
<th>Hazard Ratio</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mastectomy</td>
<td>.009</td>
<td>0.392</td>
<td>0.195-0.789</td>
</tr>
<tr>
<td>Adjuvant RT</td>
<td>.045</td>
<td>0.336</td>
<td>0.116-0.974</td>
</tr>
<tr>
<td>pCR</td>
<td>&lt;.001</td>
<td>0.075</td>
<td>0.021-0.267</td>
</tr>
<tr>
<td>Total LNs sampled</td>
<td>.011</td>
<td>0.950</td>
<td>0.913-0.988</td>
</tr>
</tbody>
</table>

Abbreviations: LNs, lymph nodes; pCR, pathologic complete response; RT, radiation therapy.

---

whole-breast/chest wall RT with nodal irradiation.
Patients with residual disease also had high rates of
DF and poor OS, and no difference in DF or OS was
seen between patients with ypT+ ypN0 and those
with ypT+ ypN+ disease. These results suggest that
any residual disease following NAC, whether in the
breast alone or in the breast and the LNs, is a pre-
dictor of poor prognosis in this patient population.
In contrast, no patient who achieved pCR follow-
ing NAC experienced LRR, and the incidence of DF
was low. These results corroborate other published
series showing pCR to be the strongest predictor of
outcome after NAC.\textsuperscript{10,14} Whether patients who
achieve a pCR will have low rates of LRR without
postmastectomy or nodal irradiation is an area of on-
going investigation.

A large percentage of our cohort (38.1%) ex-
perienced DF, driven in large part by women who did
not achieve pCR following NAC. This high rate of
DF is also likely due to most of these women (>90%)
having stage II–III disease at diagnosis, making our
patient population particularly high risk. A retro-
spective analysis of 170 women aged ≤40 years treat-
ed with NAC also observed a high rate of recurrence
(29.4%) and mortality (22.9%).\textsuperscript{15} It is likely that
these women would benefit from adjuvant treatment
to improve outcomes, and several trials have evalu-
ated escalation of adjuvant therapy.\textsuperscript{16-18} The recently
published CREATE-X trial\textsuperscript{19} evaluated 910 patients
with HER2-negative breast cancer who had residual
invasive disease or LN metastases after NAC. Wom-
en were randomized to either adjuvant capecitabine or
observation. At 5 years of follow-up, the addition
of adjuvant capecitabine significantly prolonged DFS
and OS. Other efforts to improve outcomes center
around increasing rates of pCR through the escala-
tion of NAC regimens.\textsuperscript{16-18} In the 5-year follow-up
of the NeoSphere trial,\textsuperscript{22} the addition of pertuzumab
to trastuzumab + docetaxel improved long-term out-
comes in women with HER2-positive breast cancer.
This led to the accelerated FDA approval of pertu-
zumab in the neoadjuvant setting.\textsuperscript{23}

Our analysis shows that young women with breast
cancer who achieve a pCR in both the breast and the LNs experience improved outcomes, where-

---

Figure 2. Overall survival for (A) entire cohort, (B) patients treated
from 2005–2015, and (C) patients with initial diagnosis of clinical T1–
3N1 breast cancer. Abbreviations: pCR, pathologic complete response; ypN+, residual
tumor in the lymph nodes; ypT+ ypN0, residual tumor in the breast but no tumor in the lymph nodes.
spite having a pCR in the LNs, do not have better outcomes compared with those who remain LN-positive after NAC. The strengths of this study include a detailed assessment of pathologic response and patterns of failure, as well as stratification of patients based on the time frame during which they received treatment (1991–2004 vs 2005–2015), clinical stage at diagnosis, and breast cancer subtype. Our analysis differs from previously reported studies because it assesses LRR, as well as DF and OS for all patients included in the analysis. Limitations of our study include its retrospective nature and relatively small sample size. As a single-institution study, our results may not be generalizable to the population at large, but are hypothesis-generating nonetheless.

Conclusions
Our analysis demonstrates that outcomes in young women aged ≤40 years receiving NAC vary by pathologic response in the breast and the LNs. Young women who achieve pCR have excellent outcomes; however, those who achieve pCR in the LNs but have residual disease in the breast continue to have outcomes similar to those who remain LN-positive. Our data suggest that de-escalation of care in this patient population should be approached with caution until the results of NSABP B-51 are available.

References